X
skip to main content
Logo
  • September 29, 2016

    2016 Terry Fox Run update: TFRI teams show immense support, with over $105,000 raised through team/t-shirt challenge

    TFRI-funded research teams from coast to coast showed their true colours this year, turning out by the dozens in researcher-designated purple T-shirts and forming teams to raise funds for cancer research at the 36th Terry Fox Run on Sunday Sept. 18. Early estimates show the research community's fundraising efforts resulted in over $105,000 raised.

  • September 29, 2016

    Groundbreaking study finds miR-126 regulates distinct self-renewal outcomes in normal and malignant hematopoietic stem cells

    A groundbreaking new publication by Dr. John Dick’s TFRI-funded team has confirmed that miRNA expression patterns are predictive of disease outcome in leukemia, and play a powerful role in governing the fundamental properties that define the “stemness” state of human leukemia stem cells (LSCs).

  • September 29, 2016

    Montreal team discovers new molecular pathway key to understanding fat/cancer links

    A new publication from the TFRI-funded team at McGill University (Goodman Cancer Centre) studying oncometabolism and molecular pathways is bringing new hope to the battle against obesity, cardiovascular disease and diabetes with the significant discovery of a new molecular pathway that has the ability to turn fat storage cells into fat burning cells.

  • September 29, 2016

    Dual expression study helps identify B-cell lymphoma patients at high risk for CNS relapse

    Despite improvements in outcome in diffuse large B-cell lymphoma (DLBCL) in the monoclonal antibody rituximab treatment era, central nervous system (CNS) relapse continues to occur and typically is incurable. Identifying high-risk patients is essential to focus on effective prophylaxis strategies. To date, there have not been any identified robust biomarkers to predict those at high risk. Previous seminal studies from the BC Cancer Agency have identified MYC and BCL2 dual expression to be associated with poor outcome. Importantly, a study published in Blood (May 2016) by a TFRI-funded team suggests that dual expression of MYC and BCL2 tested by immunohistochemistry (IHC) is associated with an increased risk of CNS relapse.

  • September 29, 2016

    Ovarian cancer: Mapping the clonal spread

    A team of B.C.-based, TFRI-funded scientists are breaking new ground with a recent study that tracked the clonal spread and intraperitoneal mixing of high-grade serous ovarian cancer (HGSOvCa), the deadliest subtype of the disease.

  • September 29, 2016

    New class of small molecules enhances OV replication

    An innovative paper by Dr. Jean-Simon Diallo (TFRI-funded Canadian Oncolytic Virus Consortium (COVCo) and collaborators Drs. Jeffrey Smith and Christopher Boddy was published in Scientific Reports (May 2016). They discovered and developed a class of new small molecule compounds that selectively enhance oncolytic viruses (OV) in cancer tissue, making them more likely to destroy tumour cells and eradicate the disease.

  • September 29, 2016

    Ultrasound, imaging effective tools to monitor treatment response

    Terry Fox-funded researchers have made a critical finding in monitoring breast cancer patient response to chemotherapy treatment: patient response to treatment can be detected in as little as one week by using optics and ultrasound respectively instead of waiting the traditional four to six months. Their findings were published in Oncotarget (March 2016).

  • September 27, 2016

    TFRI's 2017 ASM meeting date, location

    In 2017, TFRI will hold its Annual Scientific Meeting on November 4th to coincide with the national meeting of the Canadian Cancer Research Conference in Vancouver (Nov. 5-7th). Stay tuned for more details.

Back to Top